<DOC>
	<DOCNO>NCT00600964</DOCNO>
	<brief_summary>This protocol run determine best phase II dose schedule obatoclax patient previously untreated CLL .</brief_summary>
	<brief_title>A Phase I/II Study GX15-070MS Untreated CLL</brief_title>
	<detailed_description>Both 1 hour 3 hour infusion obatoclax every 3 week evaluate ascend dos .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Histologically cytologically confirm BCLL Previous standard systemic chemotherapy , include fludarabine . There limitation additional , allowable type amount prior therapy . Acute toxicities prior therapy must resolve ≤Grade 1 Age ≥18 year ECOG Performance Status ≤1 Life expectancy &gt; 8 week Patients receive investigational agent ( e.g. , another IND ) commercial agent therapy administer intent treat malignancy Patients history seizure disorder Pregnant woman woman breast feed HIVpositive patient receive combination antiretroviral therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>CLL</keyword>
	<keyword>obatoclax</keyword>
</DOC>